Long-term follow-up for people from the RACE study
Part of Blood & lymphatic clinical trials.
This study checks on people who took part in the earlier RACE trial and collected long-term health information. It helps researchers understand how the treatments given in that trial affect patients over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have participated in the earlier RACE trial (NCT02099747).
- In that earlier trial, you received ATGAM and cyclosporine (with or without eltrombopag).
- You must agree to be contacted and share information for long-term follow-up.
- You must be able to provide informed consent for this long-term data collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
This study follows people who have already finished treatment with the study drug gamgertamig and are doing well. It checks on their health over time to see how long the benefits last.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study is for people who already received the experimental treatment azer-cel in a previous trial. It will follow you over the long term to see how you're doing and monitor any lasting effects.
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
Hear when a new Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.